Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 10, 2025Jurnal Farmasi Sains dan PraktisOpen Access

Study of Adverse Drug Reactions of Linezolid in Drug Resistant Tuberculosis Patients

View Full Paper
Ask AI
Bookmark
Share

Authors

RSRinto SusiloESElza SundhaniISIndah Setyaningsih

Discussion

Loading...

Member takes

Overview

Observational analysis revealed a 32.6% incidence of Linezolid adverse drug reactions in DR TB patients, indicating a need for monitoring and tailored therapies.

Key Points

  • The incidence of adverse drug reactions (ADRs) related to linezolid was found in 70 out of 215 drug-resistant tuberculosis patients.
  • Hematological disorders were reported as the most common form of ADRs, representing 89% of all cases observed.
  • The study employed a retrospective cross-sectional design at two hospitals to assess ADRs related to linezolid treatment.
  • Personalized monitoring of linezolid blood levels is crucial for minimizing severe ADRs and optimizing therapy outcomes.

Cite This Study

Susilo et al. (2025) studied this question.

synapsesocial.com/papers/68e861a57ef2f04ca37e4707https://doi.org/10.31603/pharmacy.v11i2.12472
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Profiling adverse reactions to novel drug-resistant tuberculosis regimens containing bedaquiline and linezolid2026
  2. 2Haematological adverse effects associated with linezolid in patients with drug-resistant tuberculosis: an exploratory study2026
  3. 3Increased risk of adverse drug reactions by higher linezolid dose per weight in multidrug-resistant tuberculosis2024 · 13 citations
  4. 4P59 Linezolid in short- term regimens for drug-resistant TB: balancing efficacy and toxicity2025
  5. 5Prevalence and factors associated with Haematological side effects in MDR/RR-TB Patients on Linezolid-Based Regimens in Uganda: A Multicentre Retrospective Study2025